Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Update

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 48,137 shares, a drop of 83.9% from the May 31st total of 298,780 shares. Based on an average daily trading volume, of 825,528 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Daiichi Sankyo Stock Up 0.5%

OTCMKTS DSNKY opened at $15.77 on Friday. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50. The company’s 50 day simple moving average is $16.55 and its 200 day simple moving average is $18.59. The company has a market capitalization of $29.38 billion, a P/E ratio of 16.78, a PEG ratio of 2.70 and a beta of -0.16. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. Equities research analysts expect that Daiichi Sankyo will post 0.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.